Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious ...

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek ...

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...